A5052457903- HER2/EGFR in Cancer Research
- Angiogenesis and VEGF in Cancer
- Cancer Treatment and Pharmacology
- Medicinal Plant Pharmacodynamics Research
- Flavonoids in Medical Research
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
- Chemokine receptors and signaling
- Glycosylation and Glycoproteins Research
- Cancer therapeutics and mechanisms
- Multiple Myeloma Research and Treatments
- Estrogen and related hormone effects
- Pluripotent Stem Cells Research
- Peptidase Inhibition and Analysis
- Retinoids in leukemia and cellular processes
- Click Chemistry and Applications
- Animal Genetics and Reproduction
- Hematopoietic Stem Cell Transplantation
- RNA Interference and Gene Delivery
- Diet and metabolism studies
- Adipose Tissue and Metabolism
- Nanofabrication and Lithography Techniques
- Mesenchymal stem cell research
- Galectins and Cancer Biology
- Tissue Engineering and Regenerative Medicine
Glykos (Finland)
2016-2024
Finnish Red Cross
2009-2013
The expression of the epitopes recognized by monoclonal antibodies Tra-1-60 and Tra-1-81 is routinely used to assess pluripotency status human embryonic stem cells (hESCs) induced pluripotent (iPS) cells. Although it known that are carbohydrates, exact molecular identity these has been unclear. Glycan array analysis with more than 500 oligosaccharide structures revealed specific binding two molecules containing terminal type 1 lactosamine: Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAc...
Antibody-drug conjugates (ADCs) offer a combination of antibody therapy and specific delivery potent small-molecule payloads to target cells. The properties the ADC molecule are determined by balance its components. efficacy payload component increases with higher drug-to-antibody ratio (DAR), while homogeneous DAR = 8 ADCs easily prepared conjugation four accessible hinge cystines. However, use hydrophobic has permitted only 2–4, due poor pharmacokinetics aggregation problems. Here, we...
Umbilical cord blood (UCB) is an efficient and valuable source of hematopoietic stem cells (HSCs) for transplantation. In addition to HSCs it harbours low amounts mesenchymal (MSCs). No single marker identify blood-derived cells, or indicate their multipotent phenotype, has been characterized so far. SSEA-3 -4 are cell surface globoseries glycosphingolipid epitopes that commonly used as markers human embryonic where rapidly disappears when the start differentiate. Lately have also observed...
Antibody-drug conjugates (ADCs) are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. The idea behind ADC technology is remarkable it combines highly targeting capacity monoclonal antibodies with cancer-killing ability potent cytotoxic agents. continuous development improved ADCs requires systematic studies on nature effects warhead modification. Recently, we focused hydrophilic modification monomethyl...
There is an increasing interest in the modification of cell surface glycosylation to improve properties therapeutic cells. For example, affects biodistribution mesenchymal stromal cells (MSCs). Metabolic glycoengineering efficient way modify surface. The mammalian biosynthetic machinery tolerates unnatural sialic acid precursor, N-propanoylmannosamine (ManNProp), and incorporates it into glycoconjugates. We show here by mass spectrometric analysis N-glycans that about half N-acetylneuraminic...
Abstract Antibody–drug conjugates (ADCs) are promising alternatives to naked antibodies for selective drug‐delivery applications and treatment of diseases such as cancer. Construction ADCs relies upon site‐selective, efficient mild conjugation technologies. The choice a chemical linker is especially important, it affects the overall properties ADC. We envisioned that hydrophilic bifunctional linkers based on carbohydrates would be useful class derivatization agents construction linker–drug...
Antibody-drug conjugates (ADC) have shown impressive clinical activity with approval of many agents in hematologic and solid tumors. However, challenges remain both efficacy safety ADCs. This study describes novel trastuzumab-auristatin the hydrophilic monomethylauristatin E (MMAE) prodrug MMAU, optimization a glycopeptide linker leading to wider therapeutic window. Trastuzumab was conjugated auristatin payloads via series linkers using stabilized maleimide handle. The ADCs were...
CD33 (Siglec-3) is a cell surface receptor expressed in approximately 90% of acute myeloid leukemia (AML) blasts, making it an attractive target for therapy AML. Although previous CD33-targeting antibody-drug conjugates (ADC) like gemtuzumab ozogamicin (GO, Mylotarg) have shown efficacy AML treatment, they suffered from toxicity and narrow therapeutic window. This study aimed to develop novelADCwith improved tolerability wider GLK-33 consists the anti-CD33 antibody lintuzumab eight mavg-MMAU...
Abstract SAR566658 antibody drug conjugate (ADC) is a humanized DS6 (huDS6) conjugated through cleavable linker to the cytotoxic maytansinoid derivative DM4 that has been evaluated in clinical setting. The purpose of our work was; 1) characterize epitope targeted by anti on mucin1, 2) determine prevalence antigen expression patient population and 3) further explore preclinical activities ADC. Murine monoclonal (muDS6) was generated from serous ovary adenocarcinoma immunization...
<p>Ex vivo cytotoxicity assays with leukemia blast samples.</p>
<p>Supplementary Methods and Results</p>
<p>GLK-33 binding and internalization to CD33+ cells.</p>
<p>Characterization of overconjugated GLK-33 batch in rat tolerability and toxicokinetic study.</p>
<p>Supplementary Methods and Results</p>
<p>Characterization of LN-mcvc-MMAE DAR4 (lintuzumab vedotin).</p>
<div>Abstract<p>CD33 (Siglec-3) is a cell surface receptor expressed in approximately 90% of acute myeloid leukemia (AML) blasts, making it an attractive target for therapy AML. Although previous CD33-targeting antibody–drug conjugates (ADC) like gemtuzumab ozogamicin (GO, Mylotarg) have shown efficacy AML treatment, they suffered from toxicity and narrow therapeutic window. This study aimed to develop novelADCwith improved tolerability wider GLK-33 consists the anti-CD33...
<p>GLK-33 binding and internalization to CD33+ cells.</p>
<p>Ex vivo cytotoxicity assays with leukemia blast samples.</p>
<p>Comparison of MTD and TI GLK-33 with comparator ADCs.</p>